First Report Customer Care 
All time: 4.6

Latest / Last 30 Days: 5.0

527 Reviews

Credit Rating - THE PHARMA DEVELOPMENT AND MANUFACTURING CONSULTANCY LIMITED

ANALYSIS
Credit Risk Update: ACCOUNTS DUE FLAG: THE PHARMA DEVELOPMENT AND MANUFACTURING CONSULTANCY LIMITED, 27 BROCKLEHURST WAY, MACCLESFIELD, SK10 2HY. The legal status is a Private Limited Company and the current status at the registry of companies is Active - Proposal to Strike off. The company was incorporated on 9 November 2016.

The accounts next due date is 9 August 2018. There are no mortgages.

The above was based on public record information as at 4 November 2024 and may not reflect the current status. Please access the current report to ascertain the current status and credit rating.
SUMMARY
Registered Number: 10470918
Date Incorporated: 9 November 2016
Date Latest Accounts: Unknown
BUSINESS INFORMATION
Legal Form: Private Limited Company
Previous Names: None
Registered Number: 10470918
Annual Return: Unknown
Registered Office: 27 BROCKLEHURST WAY, MACCLESFIELD, SK10 2HY
SIC Code and Operations: 74909
SECURED CREDITORS
Number of Mortgages 0
Satisfied Mortgages 0
Part Satisfied Mortgages 0
Unsatisfied Mortgages 0
CREDIT RISK RATING
This is the credit risk assessment used by one of the top UK credit reference agencies.
Risk Score (1-100):

THE PHARMA DEVELOPMENT AND MANUFACTURING CONSULTANCY LIMITED

Click Here

to view this information

Risk Assessment:
Credit Rating:



First Report Score: (0-10):

Financial Status Guide:
10  trafficlight Very Strong
9   Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical
Report Created On 14 November 2024 Copyright © 2024 First Report Ltd


Recent Searches

Reg No. Reg Name Status
14493663 THE PHARMA LEEDS LTD Active
07234765 THE PHARMA LETTER LIMITED Active
13306759 THE PHARMA LOOP LIMITED Active
15387387 THE PHARMA MASTERS LIMITED Active
11672982 THE PHARMACBD LIMITED Active - Proposal to Strike off

In using this service you agree to the Terms and Conditions

© 2024 First Report Ltd